title: 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.
abstract: In a study of 99 consecutive patients with "idiopathic" eosinophilia, clonal T-cells were demonstrated in blood, bone marrow, or other tissue samples of 14 patients including 6 who had an overt T-cell malignancy. The remaining eight patients (approximately 8%) with an "Occult" T-cell clone had predominantly cutaneous disease and FIP1L1-PDGFRA was absent in all six evaluable patients. Two patients were effectively treated with low-dose oral cyclophosphamide or methotrexate whereas Gleevec treatment was ineffective in another two patients. Two patients (25%) transformed into cutaneous T-cell lymphoma after 3-8 years of eosinophilic prodrome.
authors.affiliation: Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: C
authors.initials: C
authors.lastname: Vaklavas
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: J
authors.initials: J
authors.lastname: Butterfield
authors.forename: R
authors.initials: R
authors.lastname: Ketterling
authors.forename: S
authors.initials: S
authors.lastname: Verstovsek
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: A
authors.initials: A
authors.lastname: Pardanani
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D002999:Clone Cells; D003520:Cyclophosphamide / Q000008:administration & dosage; D004802:Eosinophilia / Q000150:complications* / Q000276:immunology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007945:Leukemia, Lymphoid / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage; D015995:Prevalence; D011743:Pyrimidines / Q000008:administration & dosage; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000378:metabolism
chemical_list: D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha; D008727:Methotrexate